Elekta stock
Price history
+42.39% over the period1 year: from kr 42.56 (November 20, 2025) to kr 60.60 (November 20, 2026), +42.39%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | kr 60.60 |
| October 30, 2026 | kr 59.70 |
| September 30, 2026 | kr 52.80 |
| August 31, 2026 | kr 54.30 |
| July 31, 2026 | kr 48.38 |
| June 30, 2026 | kr 49.42 |
| May 29, 2026 | kr 53.70 |
| April 30, 2026 | kr 53.25 |
| March 31, 2026 | kr 55.20 |
| February 27, 2026 | kr 58.05 |
| January 30, 2026 | kr 57.20 |
| December 30, 2025 | kr 56.75 |
| November 28, 2025 | kr 58.00 |
| November 20, 2025 | kr 42.56 |
At a glance
The company
Medical technology company providing radiation therapy, stereotactic radiosurgery, brachytherapy and neurosurgery solutions for cancer and brain disorder treatment
Latest results
Quarter to July 31, 2026 · EPS kr 0.69 (estimate kr 0.46)
Next event
Dividend
TickerLandia's take on Elekta
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−9.15% from the 52-week high
Analysts · 15 analysts
Average targetkr 59.05−2.56% vs. price
Buy 5 · Hold 3 · Sell 7 · Hold
TickerLandia Fingerprint: Elekta
Compared with similar companies: very low profitability, very low financial strength, and very high dividend.
Financials and price compared with 31 companies in the medical devices industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricelow27
How much it costs relative to what it produces.
Metric Value Position in group Price/book 3.28 44 EV/EBITDA 15.9 55 Price/sales 1.44 5 Forward P/E 12.9 5 Profitabilityvery low7
How much it earns on revenue and capital.
Metric Value Position in group ROA 3.4% 5 Gross margin 39.6% 15 ROE −4.3% 5 Operating margin 9.2% 8 Net margin −2.2% 5 Earnings stabilitylow31
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 2.8% 53 Loss-making yearscounts in reverse: lower means more earnings stability 1 of 5 annual reports 10 Growthlow37
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) −0.30% 11 Revenue growth (year over year) −3.00% 5 Earnings growth (year over year) +146.40% 95 Financial strengthvery low12
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 2.46 18 Debt/equitycounts in reverse: lower means more financial strength 0.90 11 Current ratio 0.86 8 Interest coverage 4.79 8 Dividendvery high88
How much it returns to shareholders, and for how long.
Metric Value Position in group Payout ratiopays out more than its earnings 315.8% 98 Consecutive dividend years 22 years 68 Dividend yield 3.8% 98 Market momentumvery strong85
How the stock has moved compared with the market.
Metric Value Position in group 1-year return +42.39% 87 Distance from 200-day average +11.37% 83 Riskaverage56
How much the price swings.
Metric Value Position in group Volatility (60 days) 27.5% 50 Maximum drawdown (12 months) 27.7% 61
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Elekta is cheaper than similar companies
Elekta's Forward P/E: 12.5, −46% against the median of a group of 11 similar companies (23.1).
Compared with 11 similar companies
| Metric | Elekta | Position in the group | Band |
|---|---|---|---|
| Forward P/E | 12.5 | Low | |
| Operating margin | 9.2% | Low | |
| ROE | -4.3% | Low | |
| Debt/equity | 0.90 | High | |
| Price/book | 3.18 | Middle |
Grey band: the middle half of the group; tick: the median; dot: Elekta. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
kr 3.54B
Latest quarter · Q to Jul 2026
Net income
kr 264M
Latest quarter · Q to Jul 2026
Quarterly net margin
7.5%
Latest quarter · Q to Jul 2026
Numbers and valuation
Full valuation- Market cap
- kr 23.15B
- EPS
- -kr 0.95
- Volume
- 1.18M
- Daily trading
- €7.1M
- Dividend yield
- 3.96%
How Elekta is changing
All resultsRevenue grew 4.0% a year on average over the last 5 years
Operating margin fell from 11.8% to 8.2%
Profitable in 4 of 5 fiscal years
Returns
Elekta returns with dividends
kr 1,000 invested in Elekta 5 years ago, on November 22, 2021, would be worth kr 684 today with dividends reinvested: −31.58% in total, −7.32% per year. On price alone it would be kr 567 (−43.31%).
| Period | Elekta | kr 1,000 becomes |
|---|---|---|
| 1 month | +8.60% | kr 1,086 |
| 6 months | +1.17% | kr 1,012 |
| Year to date | +6.78% | kr 1,068 |
| 1 year | +48.75% | kr 1,487 |
| 3 years | −21.15% | kr 788 |
| 5 years | −31.58% | kr 684 |
| 10 years | −3.01% | kr 970 |
From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment
The chart in detail
Elekta: technical analysis
Elekta is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 57.6% below its all-time closing high (kr 143.00, November 14, 2019).
- Trend
- Upward
- RSI (14 sessions)
- 55
- Between 30 and 70
- vs 200-session average
- +11.37%
Support and resistance
Price areas where Elekta has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistancekr 62.73+3.51%2 touches, last on May 27, 2026
- Last pricekr 60.60
- Supportkr 59.30−2.15%2 touches, last on January 21, 2026
- Supportkr 57.85−4.54%2 touches, last on April 17, 2026
- Supportkr 56.50−6.77%3 touches, last on August 24, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 27.5%
- Largest fall in the last year
- −27.75%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Elekta: seasonality
Average monthly price change over 33 years
Over the last 33 years, the strongest month for Elekta has been November: +6.05% on average, positive in 20 years out of 32. The weakest has been December: −1.28% on average, positive in 15 years out of 32.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +3.46% | +1.27% | 18 of 32 |
| February | −0.94% | −1.33% | 14 of 32 |
| March | +0.39% | +0.27% | 16 of 32 |
| April | +0.07% | +0.56% | 18 of 33 |
| May | +4.04% | +6.03% | 23 of 33 |
| June | −0.87% | +0.89% | 17 of 33 |
| July | +1.25% | +1.45% | 20 of 33 |
| August | −0.23% | −2.99% | 15 of 33 |
| September | −1.00% | +0.98% | 17 of 33 |
| October | +2.20% | +1.99% | 21 of 33 |
| November | +6.05% | +1.61% | 20 of 32 |
| December | −1.28% | −1.07% | 15 of 32 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Elekta and its competitors
Radiation therapy equipment for treating cancer is the starting point of Elekta's activities, including linear machines such as Elekta Unity, Elekta Evo and Elekta Versa HD, alongside stereotactic radiosurgery systems such as the Esprit gamma knife. The company also sells brachytherapy products, among them Oncentra Brachy and Elekta Flexitron, and the Leksell Vantage neurosurgery system. Its clinical solutions are offered in the Americas, Europe, the Middle East, Africa and the Asia Pacific, and it provides veterinary radiation therapy solutions as well as clinical and professional services through Elekta Care.
- Headquarters
- Stockholm, Sweden
- Employees
- 3,996
- Founded
- 1972
- Chief executive
- Jakob Just-Bomholt
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| ElektaEKTA.B | $2.27B | 9.2% | — | +1.17% |
| Medacta GroupMOVE | $2.41B | 15.2% | 27.7 | −30.49% |
| GN Store NordGN | $2.46B | 10.9% | 90.2 | +22.10% |
| ChemoMetecCHEMM | $1.75B | 49.1% | 59.9 | +99.42% |
| AmbuAMBU.B | $3.4B | 13.2% | 36.7 | +32.33% |
| El.En.ELN | $1.44B | 14.7% | 20.7 | +10.78% |
Same industry or related industries, similar size. Compare Elekta with its competitors · Full profile
